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AbstrACt
Introduction As many as 250 million children under the 
age of  
5 may not be reaching their full developmental potential 
partly due to poor nutrition during pregnancy and the 
first 2 years of life. Micronutrients, including vitamin B
12, 
are important for the development of brain structure 
and function; however, the timing, duration and severity 
of deficiencies may alter the impact on functional 
development outcomes. Consequently, to fully explore the 
effect of vitamin B
12 on cognitive function, it is crucial to 
measure neurodevelopment at different ages, in different 
populations and with vitamin B
12 supplementation 
at different times during the critical periods of 
neurodevelopment.
Methods and analysis In this project, we follow up 
children from four recently completed randomised 
placebo-controlled trials of oral vitamin B
12 
supplementation, two in India and two in Tanzania, to 
explore the long-term effects on neurodevelopmental 
outcomes and growth. All the included trials provided 
at least two recommended dietary allowances of 
oral vitamin B
12 daily for at least 6 months. Vitamin 
B12 was supplemented either during pregnancy, early 
infancy or early childhood. Primary outcomes are 
neurodevelopmental status, cognitive function and growth 
later in childhood. We apply validated and culturally 
appropriate instruments to identify relevant developmental 
outcomes. All statistical analyses will be done according 
to intention-to-treat principles. The project provides an 
excellent opportunity to examine the effect of vitamin B
12 
supplementation in different periods during early life and 
measure the outcomes later in childhood.
Ethics and dissemination The study has received 
ethical approvals from all relevant authorities in Norway, 
USA, Tanzania and India and complies fully with ethical 
principles for medical research. Results will be presented 
at national and international research and policy meetings 
and published in peer-reviewed scientific journals, 
preferably open access.
trial registration number NCT00641862 (Bangalore); 
NCT00717730, updated CTRI/2016/11/007494 (Delhi); 
NCT00197548 and NCT00421668 (Dar es Salaam).
IntroduCtIon 
New estimates based on proxy measures of 
stunting and poverty indicate that as many 
as 250 million children under the age of 5 
from low-income and middle-income coun-
tries (LMICs) are at risk of not fulfilling their 
developmental potential partly because of 
poor nutrition during pregnancy and the 
first 2 years of life.1 Malnutrition and micro-
nutrient deficiencies represent a major chal-
lenge to child health in many LMICs and are 
strengths and limitations of this study
 ► The current project takes advantage of recently 
completed randomised placebo-controlled trials 
to study long-term effects of oral vitamin B12 
supplementation on neurodevelopmental outcomes 
and growth in children in Tanzania and India.
 ► The project provides an excellent opportunity to 
examine the effect of vitamin B12 supplementation 
during different periods of the critical first 1000 days 
and measure the outcomes later in childhood.
 ► The studies were not designed to follow the children 
up beyond the time of supplementation, which may 
lead to a somewhat high rate of loss to follow-up.
 ► The effect measures may be difficult to standardise 
across the different studies.
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associated with suboptimal cognitive function and poor 
growth.2 Many children in South Asia and Africa suffer 
from deficiencies of several nutrients including vitamin 
B12.
3–7 
Why vitamin b12 may be important for the developing brain
Vitamin B12 plays a key role in normal brain development 
and function and is required for the folate-dependent 
enzyme, methionine synthase, which is necessary for the 
synthesis of methionine from homocysteine.8 Methionine 
in its activated form, S-adenosylmethionine, is the major 
methyl group donor used in human methylation reactions, 
including methylation of DNA and RNA. Deficient meth-
ylation reactions in the central nervous system can impair 
the methylation of myelin basic protein in the central as 
well as peripheral nervous system.9 The production of 
myelin is a key component of brain development from 
gestation, throughout childhood and well into middle 
age.10 The myelination of the brain is of importance for 
multiple brain systems and is highly related to neuro-
development and subsequent cognitive functioning.11 
Vitamin B12 also serves as a cofactor in numerous cata-
lytic reactions in the human body, which are required 
for neurotransmitter synthesis and functioning. Vitamin 
B12 deficiency may cause pernicious anaemia with similar 
effects on cognitive development and functioning as 
anaemia caused by iron deficiency.12 Vitamin B12 defi-
ciency can also result in neuropathy through degener-
ation of nerve fibres and irreversible brain damage.13 
However, although subtle vitamin B12 deficiency is very 
common, the degree to which it has significant conse-
quences for neurodevelopment and cognitive function is 
not established.14 15
Vitamin b12 and neurodevelopment
There is ample evidence that vitamin B12 is important for 
cognitive development.11 In observational studies among 
adults and elderly, low levels of vitamin B12 are associated 
with cognitive decline and dementia.16 Although there are 
fewer observational studies in children, the association 
between vitamin B12 status and cognitive functioning has 
also been documented from early infancy to adolescence. 
Neonatal severe vitamin B12 deficiency causes failure to 
thrive and possible irreversible neurological manifesta-
tions.12 17 A study in the Netherlands showed that infants 
fed on a macrobiotic diet, which is low on vitamin B12, had 
delayed gross motor, speech and language development 
compared with infants on an omnivore diet.18 In adoles-
cence, these same children who were fed a macrobiotic 
diet for the six first years of life had poorer performance 
on cognitive tests, independent of their current vitamin 
B12 status, compared with adolescents who were fed on 
an omnivorous diet.19 In an Indian infant cohort, we also 
demonstrated that poor vitamin B12 status was associated 
with lower scores on the Mental Development Index in 
the Bayley Scales of Infant and Toddler Development 
second edition.4 In a study from Nepal, we were able to 
demonstrate associations between early vitamin B12 status 
(2–12 months) and cognitive functioning 5 years later.20 
These long-term associations remained strong, even 
after adjusting for several potential confounders. There 
is also evidence for the significance of vitamin B12 to the 
developing brain in a few clinical trials. In a randomised 
controlled trial (RCT) Indian children aged 6–30 months 
were administered placebo or approximately twice the 
recommended daily allowances of vitamin B12 and/or folic 
acid for 6 months. Children provided with vitamin B12 and 
folic acid scored higher on a neurodevelopment assess-
ment compared with the placebo group.21 The effects 
were most prominent in stunted children or children less 
than 2 years of age. A favourable effect of vitamin B12 was 
also demonstrated on motor development in two RCTs 
involving Norwegian infants with developmental regres-
sions and signs of vitamin B12 deficiency 1 and 6 months 
following a 400 µg injection of vitamin B12.
22 23
Knowledge gaps
There is a need to clarify to what extent improving vitamin 
B12 status impacts developmental outcomes in children 
in LMICs. It is also important to identify populations in 
which such interventions can be beneficial and at what 
age vitamin B12 administration is most effective.
11 Most 
studies in this field have used only motor function tests or 
general neurodevelopment assessments,21 22 24 while less 
is known on the effect of vitamin B12 on specific cogni-
tive functions such as executive functions, attention and 
sensorimotor and visuospatial abilities.20 The functions 
and areas under development are most sensitive to nega-
tive influences and will provide the most specific outcomes 
in assessments.25 26 Consequently, to fully understand 
findings in developmental assessments, we must consider 
the developmental timing of an exposure, in this case, 
vitamin B12 supplementation (or lack thereof), as well as 
the timing of the assessment.25 Measuring neurodevelop-
ment at different ages, in different populations and the 
effect of exposure at different times during the critical 
periods of neurodevelopment is needed to understand 
the role of vitamin B12 in cognition.
Research on the impact of vitamin B12 on the neuro-
physiological outcomes in children is scarce. Event-re-
lated potential (ERP) are non-invasive, reliable measures 
of neurophysiological brain function27 that provide direct 
measure of underlying neural activity of higher mental 
processes. Behavioural assessments may sometimes not be 
sensitive enough to detect these small changes in brain 
functions28 and these neurophysiological processes may 
be important correlates of the cognitive abilities and give 
new insight into the nutritional impact on the developing 
brain.29
study objECtIVEs
The aim of the current study, the Vitabeginning project, 
is to determine the long-term effects of vitamin B12 
supplementation given during the first 1000 days of life 
on neurodevelopmental outcomes and growth.
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General objective
 ► To provide evidence for the role of vitamin B12 
supplementation in pregnancy or early childhood on 
neurodevelopment in vulnerable children in LMICs.
specific objectives and objectives of the separate studies
 ► In North Indian children aged 6 to 30 months at 
enrolment, measure to what extent 6 months’ admin-
istration of vitamin B12 (1.8 µg) with or without folic 
acid (150 µg) improves neurodevelopment and cogni-
tive function 5 years after the end of supplementation. 
Age range at follow-up is 7–9 years.
 ► In South Indian children, measure to what extent 
administration of daily vitamin B12 (50 µg) in combi-
nation with iron and folic acid from 14 weeks’ gesta-
tional age through 6 weeks postpartum improves 
neurodevelopment, cognition and neurophysiolog-
ical function in childhood. Age range at follow-up is 
5–6.5 years.
 ► In Tanzanian children, measure to what extent 
administration of vitamin B12 (50 µg) given with other 
vitamins from 11 to 17 weeks’ gestational age until 
delivery improves neurodevelopment and cognitive 
function up to school age. Age range at follow-up is 
11–15 years.
 ► In Tanzanian children, measure to what extent 
administration of vitamin B12 (1 mg) given with other 
vitamins from week 6 to 18 months of age improves 
neurodevelopment and cognitive function up to 
school age. Age range at follow-up is 7–10 years.
 ► To estimate the effect of vitamin B12 administration on 
certain domains of neurodevelopment using pooled 
data from all of the above studies.
MEthods And AnAlysIs
study design and interventions
This study is a follow-up of four recently completed double-
blind randomised placebo-controlled trials conducted in 
lower socioeconomic, semiurban and urban populations 
in Delhi (India),21 30 Bangalore (India)31 and Dar es 
Salaam (Tanzania)32 33 in 2001– 2011. All trials provided 
at least two recommended dietary allowances (RDA) of 
vitamin B12 daily (2×2.6 µg for adults and 9 µg for small 
children) for at least 6 months, with no vitamin B12 
supplementation in the placebo groups. The two studies 
that enrolled pregnant women provided the highest dose 
of vitamin B12 (50 µg daily, which is approximately 20 
times the RDA). An overview of the original trials and the 
follow-ups is presented in table 1.
Table 1 Overview of study populations, study period and exposure in the original trials and in the Vitabeginning follow-up 
study
Characteristics Bangalore Delhi Dares Salaam
Original trials
  Trial registration 
number
NCT00641862 NCT00717730 NCT00197548 NCT00421668
  Intervention period 09.2010–08.2011 01.2010–03.2011 08.2001–02.2005 07.2007–05. 2011
  Original sample size 366 1000 8468 2400
  Exposure Vitamin B12* Vitamin B12 and/or folic acid† Maternal 
multivitamins‡
Multivitamins and/
or zinc§
  Timing of exposure Pregnancy (daily 
supplement from 
<14 weeks gestational 
age through 6-week 
postpartum)
Infancy/early childhood (daily 
supplement for 6 months from 6 
to 30 months)
Pregnancy (daily 
supplement from 11-
17 weeks until delivery)
Infancy (daily 
supplement 
from 6 weeks to 
18 months)
Vitabeginning follow-ups
  Expected sample size 230 800–900 366 446
  Age range at follow-up 5–6.5 years 7–9 years 11–15 years 7–10 years
  Start date of enrolment 01.2015 10.2016 07.2015 07.2015
  Expected date for 
study completion
Estimated 07.2017 Estimated 11.2017 Estimated 11.2017 Estimated 
11.2017
*From <14 weeks gestational age to 6 weeks postpartum vitamin B12 50 µg daily. In addition, all women were given iron and folic acid 
supplementation throughout pregnancy.
†From 6 to 30 months for 6 months; four groups: vitamin B12, vitamin B12 +folic acid, folic acid and placebo, doses >12 months: vitamin 
B12 1.8 µg and folic acid 150 µg (half doses for <12 months).
‡From 12 to 27 weeks gestational age until delivery: multivitamin B12 50 µg, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, niacin 
100 mg, vitamin C 500 mg, vitamin E 30 mg, folic acid 0.8 mg.
§From 6 weeks to 18 months, four groups; multivitamin + zinc, vitamin Z and placebo. Multivitamin <6m: vitamin B12 1 mg, vitamin B1 0.5 mg, 
vitamin B2 0.6 mg, vitamin B 60.6mg, niacin 4 mg, folic acid 130 µg, vitamin C 60 mg, vitamin E 8 mg. Zinc 5 mg >6 months multivitamins and 
zinc doses were double.
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In Bangalore, South India, HIV-negative pregnant 
women recruited before or at 14 weeks gestational age 
were randomised to receive a daily dose of oral vitamin 
B12 (50 µg) or a placebo through 6 weeks postpartum. The 
primary objective was to determine the effect of vitamin 
B12 supplementation in improving maternal vitamin B12 
status. Enrolment was completed in September 2010, 
and the last enrolled infant was born in August 2011. 
Oral vitamin B12 supplementation of women throughout 
pregnancy and early lactation, in combination with stan-
dard prenatal care with routine supplementation of iron 
and folate, significantly increased the vitamin B12 status 
Table 2 Overview over inventories and data collection tools used in the different studies and the age of assessment
Outcomes to be measured Bangalore Delhi Dar es Salaam
Vitamin B12 exposure Pregnancy Child Pregnancy Child
Outcomes to be measured Age (year) Age (year) Age (year) Age (year)
General abilities
  Modified KABC-II* EACABT 5, 6 11–15 7–10
  WISC-IVINDIA 7–9
Verbal abilities
  Crichton Vocabulary Scale, Hindi edition 7–9
Neurophysiological tests
  Event-related potential† 6
Neuropsychological tests
  NEPSY-II 7–9
Questionnaires
  Brief‡ 5.5 7–9 11–15 7–10
  SDQ 6.5 7–9 11–15 7–10
  VSMS 5
Maternal assessment
  Demography 5 7–9 11–15 7–10
  Anthropometry 5, 5.5, 6, 6.5 11–15 7–10
  Home environment 5.5 11–15 7–10
Nutrition
  24-hour diet recall form 5, 5.5, 6, 6.5 7–9
  Anthropometry 5, 5.5, 6, 6.5 7–9 11–15 7–10
  Household food security questionnaire 5, 6
Medical morbidity
  Morbidity questionnaire 5, 5.5, 6, 6.5 11–15 7–10
Biomarkers
  Vitamin B12 5, 6 7–9 6–24 m§ 
  CBC, MMA, HcY, RBC folate, CRP 5, 6 7–9
  Haemoglobin 5, 6 7–9 11–15 7–10
*In Bangalore: Atlantis, number recall, word order, pattern reasoning and triangles from KABC and Koh’s Block Design Test and Verbal 
Fluency in addition; in Dar es Salaam: the EACABT with permission from Savings Brain Multisite Study (WHO/BMGF) including Atlantis, 
hand movements, footsteps, story completion, Kilifi Naming Test, ROCF, NOGO, shift, people search, literacy and numeracy, HOME, Brief-P 
(modified from MAL-ED), SDQ, BQP, in addition to verbal fluency and Koh’s Block. 
 †ENOBIO 32 (Device name)—brain monitoring and stimulation technologies, mismatch negativity, P300 (Neuroelectrics, Boston, MA) .
 ‡Different versions used in different sites: in Bangalore: Brief Parent; in Delhi: Brief Second Edition; in Dares es Salaam: Saving Brains/Gates/
WHO modified version from the malaria study. 
§On stored serum samples from Child II cohort (subject to funding).
BMGF, Bill & Melinda Gates Foundation; BQP, Behavior Questionnaire for Parents; CBC, complete blood count; CRP, C reactive 
protein; EACBT, African Cognitive Assessment Battery; HcY, homocysteine; HOME, Home Observation Measurement of the 
Environment; KABC, Kaufman  Assessment Battery for Children; MAL-ED,  Etiology, Risk Factors and Interactions of Enteric Infections 
and Malnutrition and the Consequences for Child Health and Development, MMA, methylmalonic acid; NEPSY-II, A Developmental 
NEuroPSYchological Assessment; NOGO, go/no go test for sustained attention and response control; RBC folate, red blood cell folate 
analysis; ROCF, Rey–Osterrieth complex figure; SDQ, Strengths and Difficulties Questionnaire; VSMS, Vineland Social Maturity Scale; WISC-
IVINDIA, Wechsler Intelligence Scale for Children VI, Indian version. 
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of women and their offspring.31 Neurodevelopment was 
measured at 9 and 30 months. In this follow-up study, we 
will measure the effect of maternal vitamin B12 supple-
mentation on neurodevelopment and cognitive function 
several times 5–6.5 years after supplementation and on 
neurophysiological outcomes using ERP.
In Delhi, North India, children 6–30 months of age were 
randomised to receive daily (1) vitamin B12, (2) vitamin 
B12 and folate, (3) folate or (4) placebo for 6 months. 
The supplementation included vitamin B12 (1.8 µg) 
and/or folate (150 µg) and with half doses for children 
<12 months. The primary objective was to measure 
the effect of these interventions on the incidence of 
diarrhoea and pneumonia. Neurodevelopment was a 
predefined secondary outcome and was measured in a 
subsample of 422 children. In total, 1000 children were 
enrolled between January 2010 and September 2011. 
Vitamin B12 and folic acid-supplemented children scored 
significantly higher on neurodevelopment scores at the 
age of 12–36 months, compared with those who received 
placebo.21 In this follow-up study, we will measure to what 
extent early supplementation of folic acid and/or vitamin 
B12 improves neurodevelopment and cognitive function 
5–6 years after supplementation. The study is powered to 
measure the effect of vitamin B12, folic acid and the two 
vitamins combined on neurodevelopmental outcomes. 
The follow-up study will also measure to what extent 
vitamin D status in early life is associated with neurodevel-
opmental scores in early school years.
In Dar es Salaam, Tanzania, infants 6–10 weeks of 
age born to HIV-negative mothers were randomised to 
receive daily (1) zinc, (2) multivitamins, (3) zinc + multi-
vitamin or (4) placebo. Multivitamins included vitamin 
B121 mg, B10.5 mg, B20.6 mg, B60.6 mg, niacin 4 mg, folic 
acid 130 µg, vitamin C 60 mg and vitamin E 8 mg and was 
provided alongside zinc 5 mg. Doses were doubled after 
6 months.
Children were followed for 18 months (ie, until age 19.5 
months). The primary objective was to measure the inci-
dence of diarrhoea and respiratory tract infections. Enrol-
ment was completed in December 2009, and follow-up 
ended in May 2011. Neurodevelopmental outcomes were 
assessed in a subset of children at 15 months.32 Daily zinc 
supplementation lowered the burden of diarrhoea and 
respiratory tract infections. No added benefit was seen 
from the provision of multivitamins.33
In another trial in Dar es Salaam, Tanzania on micro-
nutrients and adverse pregnancy outcomes, HIV-negative 
pregnant women at 12–27 weeks gestational age were 
randomised to receive daily oral supplementation of 
multivitamins including vitamin B12 or placebo. Multivita-
mins included vitamin B1250 µg, vitamin B120 mg, vitamin 
B220 mg, vitamin B625 mg, niacin 100 mg, vitamin C 
500 mg, vitamin E 30 mg and folic acid 0.8 mg. All women 
received prenatal iron and folate supplementation. The 
primary objective was to measure the effect of vitamin 
supplementation on fetal loss, low birth weight and severe 
preterm birth. Enrolment was completed in July 2004, 
Figure 1 Estimated required total sample sizes based on relevant effect sizes.
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and the last enrolled infant was born in February 2005. 
Multivitamin supplementation reduced the incidence 
of low birth weight and small for gestational age births 
but had no significant effects on prematurity or fetal 
death.34 The two studies from Tanzania are well suited for 
follow-up studies on potential impact of micronutrient 
supplementation on child health and neurodevelop-
mental outcomes in older children.
outcomes
Neurodevelopment, cognitive function and linear growth 
will be key outcomes in the different studies.
Neurodevelopment
Neurodevelopmental status in young children has 
been assessed by the comprehensive assessment tool 
Bayley Scales of Infant and Toddler Development third 
edition35 and the easily administered screening tool Ages 
and Stages Questionnaire third edition in the original 
studies.21 36
In the follow-up, each site use their own unique collec-
tions of tests and questionnaires (table 2). General intel-
lectual functioning is assessed by a modified Kaufmann 
ABC II (Bangalore and Dar es Salaam), the Wechsler 
Preschool and Primary Scale of Intelligence–III (Banga-
lore) or the Wechsler Intelligence Scale for Children 
VI, Indian version (Delhi). These are complemented 
by tests on specific cognitive functions by subtests from 
the developmental neuropsychological test battery A 
Developmental NEuroPSYchological Assessment, version 
2 (NEPSY-II) including attention and executive func-
tioning, language, social perception, sensorimotor and 
visuospatial processing (Delhi) and adaptive functioning 
by the Vineland Social Maturity Scale (Bangalore). 
Mental health and behaviour problems are measured by 
the parent-reported screening instrument Strengths and 
Difficulties Questionnaire and executive functions by the 
parent-reported questionnaire Behaviour Rating Inven-
tory of Executive Function (all sites). Finally, in one study 
(Bangalore), we measure neurophysiological functions 
using event-related potentials as this may yield additional 
information on the effects of nutritional deficiencies on 
brain function. In the present study, we propose to use 
two well-characterised ERPs, P-300 and Mis-match Nega-
tivity that are known to reflect higher cognitive functions 
of attention and memory (see table 2 for details on the 
assessments at each site).
Anthropometry
Weight and height are measured using standard 
methods. In Delhi, height, weight and skin fold thick-
ness were measured in children, using Seca scales 
(hight/weight) and Holtain Calipers. In Bangalore, 
weights of mothers and children were recorded using a 
digital balance (Salter’s 9016; Tonbridge) to the nearest 
100 g, and the heights were measured using a stadiom-
eter to the nearest 0.1 cm.
sample size calculation
The data for our most relevant tests are expected to 
be normally distributed. We have decided that a stan-
dardised effect size of 0.35 SD is the minimally clini-
cally relevant effect for the main psychometric tests. If 
the smallest group in any of our comparisons includes 
at least 130 children in each arm, and assuming a 
two-sided alpha error of 0.05 we will have 81%, 89% and 
98% power to detect differences for effect sizes of 0.35, 
0.4 and 0.6, respectively. As a result, all of the described 
studies have sufficient power to detect important differ-
ences between vitamin B12 and placebo recipients 
between individuals with poor and adequate vitamin 
B12 status or between other groups of other exposures 
as long as each of the groups contain at least 130 chil-
dren. Statistical powers according to standardised mean 
effect sizes of .35, 0.4 and 0.6 and total sample sizes are 
depicted in figure 1. This graph was generated using the 
‘power two means’ command in STATA V.13; it assumes 
equal group sizes and equal variances and a significance 
level of 0.05.
data collection
Data collection for the primary and secondary outcomes 
are synchronised and selected to capture the same 
domains of development using different tools. Assess-
ment tools for cognitive functions such as general abili-
ties, achievement, verbal, visual spatial and sensorimotor 
skills, memory, executive functioning, general behaviour 
and social perception and maturity are dependent on 
the child’s age. We have carefully selected well-validated 
and developmentally sensitive instruments to ensure 
detection of the relevant predictors according to age and 
research questions. Instruments are adapted to ensure 
psychometric qualities, as well as cultural and linguistic 
appropriateness of the test at each site. Clinically useful 
tests will be prioritised to improve sustainability of test 
material and knowledge of developmental assessment at 
the specific sites. Assessments are administered by trained 
psychologists in the Indian sites and by trained health-
care workers in the Tanzania site. A group of experienced 
scientists with expertise in developmental, neuropsycho-
logical and neurophysiological assessments are respon-
sible for the training and standardisation in the different 
sites.
Analysis plan
Several domains will be measured and compared between 
the study groups within each of the studies. In these anal-
yses, we will initially use the Student’s t-test for the crude 
analyses and multiple linear regression models to adjust 
for potential baseline differences and when measuring 
effect modification.
Each of the studies has several outcomes as we will 
compare both linear and ponderal growth, in addition to 
all the above-mentioned neurodevelopmental measures 
between the study groups. Thus, there will be several 
comparisons from each study, and negative and positive 
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effects will be reported to avoid focusing on spurious 
positive findings.
For each of the planned publications, we will make a 
detailed plan of analysis before commencing the analysis. 
In these plans, we will include sections on how to deal with 
multiple comparisons and whether post hoc adjustments 
will be done. In addition to these standard per-protocol 
analysis, we will consider instrumental variable analysis in 
an attempt to estimate the true effect of vitamin B12 had it 
been given to all participants in the scheduled doses and 
intervals. The random allocation will be the instrument 
in these analyses. For per-protocol analysis, participants 
who received less than 50% of the projected doses during 
the period of intervention will not be included in the 
analyses, well acknowledging that the ensuing effect esti-
mates may not only be biased but will certainly represent 
an effect higher than what can be achieved even in our 
well-resourced study setting.
For our subgroup analyses, we will include interaction 
terms to measure whether or not the subgrouping vari-
able significantly modifies the effect of the exposure of 
interest. All of our analyses will initially be done according 
to intent to treat.
We will not be able to retain the complete number of 
children from these studies. We will compare the features 
of the population that is included in this analysis with the 
population that we failed to re-enrol into the study. We 
will also detect risk factors for poor neurodevelopment 
in multiple linear or binomial regression models. We will 
include socioeconomic and seasonal factors and dietary 
intake as exposures in the analyses. A significance level of 
0.05 will be used.
EthICs And dIssEMInAtIon
Ethical and safety considerations
The exposures under investigation in this study were 
included in the original trials. Informed written parental 
consent will be taken from one or both parents of partici-
pating children prior to enrolment in the follow-up study 
and assent will be obtained from children older than 7 
years in the Delhi site. Parents unable to read or write will 
be encouraged to bring along a literate relative or neigh-
bour as an impartial witness.
relevance and benefit to society
The current project takes advantage of four recently 
completed randomised placebo-controlled trials to 
study the long-term effects of vitamin B12 supplemen-
tation on neurodevelopmental outcomes and growth 
in children in low- and middle-income countries. 
When measuring the effect of vitamin B12 on growth 
and development, long-term follow-up is important: 
vitamin B12 can be stored for years in the body, and 
the effect of an increased intake for a relatively short 
period such as 6 months may accordingly last much 
longer. Furthermore, for many of the neurodevelop-
mental outcomes, it might not be possible to estimate 
the effect of early life exposures until later in child-
hood because of limitations in the assessment tools. 
Thus, to follow children for a long time, as in this 
project, is important to fully understand the role of 
vitamin B12 for brain development and growth.
In most studies, follow-up for several years is not 
possible, so the results from our studies will be of great 
importance. Since none of the RCTs originally were 
designed for such long-term follow-up, there is risk that 
loss to follow-up can bias our effect estimates. There is, 
however, no reason to believe that the loss to follow-up 
rate will be different according to randomised regimen 
in any of the described studies. The risk of confounding 
of the main exposures (Vitamin B12 supplementation) is 
small because of the RCT design and the large number 
of randomization units. Substantial imbalances of 
potential confounding factors across study groups are 
unlikely.
If positive effects of supplementation are observed, this 
may constitute important contributions to improve child-
hood nutrition in many LMICs. However, several factors 
may have profound impact on long-term neurodevelop-
ment outcomes and growth and potentially dilute the 
effect of optimising vitamin B12 status in early life. Our 
findings, however, must be interpreted in light of the 
results from other RCTs that are measuring the effect 
of vitamin B12 supplementation on growth and develop-
ment. If anything, our findings will guide our next step in 
understanding the role of vitamin B12 nutrition on child 
growth and development: Should there be additional 
follow-ups in the ongoing studies or will the results from 
our studies discourage further studies on vitamin B12 and 
child health?
If none, or very few, of our several outcomes respond 
to vitamin B12 supplementation, alone or when given 
in combination with several other micronutrients, then 
poor vitamin B12 status is likely not an important contrib-
utor to impaired neurodevelopment. Thus, we believe 
that a negative result of our studies is also of substantial 
public health importance. 
Millions of children across the world grow up 
malnourished lacking essential nutrients, with high 
burden of infectious diseases and where parents may 
not have the resources to provide an optimal environ-
ment for nurturing care. Acting in early childhood, 
these factors may result in poorer chances for later 
success in school and work. The results from the RCTs 
can lead to dietary recommendations that can improve 
learning and academic achievements, which again can 
lift individuals from the vicious cycle of poverty and 
malnutrition. Programme designed to prevent or treat 
micronutrient deficiencies can be targeted towards 
specific recommendations. Any further evidence for the 
long-term effect of dietary supplements has potentially 
high impact and may provide sustainable improvements 
in health and equity.
The suggested studies are geared towards rapid dissem-
ination of results into national and international child 
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health promotion programme. We will actively use the 
potential influence of the international collaborators 
to ensure that our results reach the relevant health 
authorities.
Planned publications
Study results will be presented at national and interna-
tional research and policy meetings, and published in 
peer-reviewed scientific journals, preferably open access. 
We will also discuss alternative strategies to inform the 
public. We will publish scientific papers as a consortium, 
specifically directed towards developmental and neuro-
psychological assessment methodology and site-specific 
publications. We expect each of the sites to generate 
approximately five publications in high-ranked interna-
tional peer-reviewed journals.
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